Results of Buparlisib Plus Fulvestrant in HR+/HER2- Breast Cancer

May 15, 2017

Ruth O’Regan, MD, discusses results of BELLE-3, a phase III study of buparlisib (BKM120) plus fulvestrant (Faslodex) in postmenopausal women with hormone receptor (HR)-positive, HER2-negative breast cancer.